GENERAL
Gland Pharma Set To Acquire Gland Pharma USA In A $5.01-Lakh Deal
Gland Pharma Ltd has approved the acquisition of 100% equity in Gland Pharma USA Inc. (Gland US), a wholly-owned step-down subsidiary, from Gland Pharma International Pte. Ltd., a wholly-owned subsidiary, for $5.01 lakh. Upon completion of the transaction, Gland US will become a direct wholly-owned subsidiary of Gland Pharma. The company expects to complete the […]
CW Bureau
·
Sep 13, 2026
GENERAL
Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion
Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]
CW Bureau
·
Aug 4, 2026
MANUFACTURING
India Proposes Faster Medical Device Licensing Under New Draft Guidelines
India’s Union Ministry of Health and Family Welfare has proposed amendments to the Medical Devices Rules, 2017 to shorten manufacturing licence approval timelines for medical devices, a move aimed at improving regulatory efficiency, enhancing ease of doing business and accelerating the availability of quality medical devices in India. The ministry has issued a draft notification […]
CW Bureau
·
Jun 28, 2026
GENERAL
Aurobindo Pharma USA Gets USFTC Nod For $250-Mn Lannett acquisition
Aurobindo Pharma USA, Inc, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end […]
CW Bureau
·
Jun 22, 2026
GENERAL
Aurobindo Eyes $494-Mn US Market With Launch Of Tofacitinib Generic
Aurobindo Pharma has strengthened its presence in the lucrative US generics market after receiving final approval from the US Food and Drug Administration (USFDA) for Tofacitinib tablets in 5 mg and 10 mg strengths, opening the door to a market worth nearly $500 million annually. The approval allows the company to manufacture and market a […]
CW Bureau
·
Jun 4, 2026
